Etanercept: efficacy and safety for approved indications

Bibliography

• Culy CR, Keating GM. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 2002;62:2493-537
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79
   PubMed Web of Science ®Google Scholar
• Tan JK, Aphale A, Malaviya R, Mechanisms of action of etanercept in psoriasis. J Investig Dermatol Symp Proc 2007;12:38-45
   PubMed Web of Science ®Google Scholar
• Korth-Bradley JM, Rubin AS, Hanna RK, The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000;34:161-4
   PubMed Web of Science ®Google Scholar
• Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 2005;45:490-7
   PubMed Web of Science ®Google Scholar
• Nestorov I, Zitnik R, DeVries T, Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. Br J Clin Pharmacol 2006;62:435-45
   PubMed Web of Science ®Google Scholar
• Zhou H, Buckwalter M, Boni J, Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 2004;42:267-76
   PubMed Web of Science ®Google Scholar
• Lee H, Kimko HC, Rogge M, Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 2003;73:348-65
   PubMed Web of Science ®Google Scholar
• Yim DS, Zhou H, Buckwalter M, Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol 2005;45:246-56
   PubMed Web of Science ®Google Scholar
• Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 2008;58:443-6
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager JP, Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81
   PubMed Web of Science ®Google Scholar
• Zhou H, Mayer PR, Wajdula J, Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol 2004;44:1235-43
   PubMed Web of Science ®Google Scholar
• Zhou H, Patat A, Parks V, Absence of a pharmacokinetic interaction between etanercept and warfarin. J Clin Pharmacol 2004;44:543-50
   PubMed Web of Science ®Google Scholar
• Zhou H, Parks V, Patat A, Absence of a clinically relevant interaction between etanercept and digoxin. J Clin Pharmacol 2004;44:1244-51
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9
   PubMed Web of Science ®Google Scholar
• O'Dell JR, Petersen K, Leff R, Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. J Rheumatol 2006;33:213-18
   PubMed Web of Science ®Google Scholar
• Combe B, Codreanu C, Fiocco U, Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis 2006;65:1357-62
   PubMed Web of Science ®Google Scholar
• Combe B, Codreanu C, Fiocco U, Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Ann Rheum Dis 2009;68:1146-52
   PubMed Web of Science ®Google Scholar
• Keystone EC, Schiff MH, Kremer JM, Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:353-63
   PubMed Web of Science ®Google Scholar
• Johnsen AK, Schiff MH, Mease PJ, Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol 2006;33:659-64
   PubMed Web of Science ®Google Scholar
• Sharp JT, Lidsky MD, Collins LC, Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971;14:706-20
   PubMed Web of Science ®Google Scholar
• Sharp JT, Bluhm GB, Brook A, Reproducibility of multiple-observer scoring of radiologic abnormalities in the hands and wrists of patients with rheumatoid arthritis. Arthritis Rheum 1985;28:16-24
   PubMed Web of Science ®Google Scholar
• Fries JF, Bloch DA, Sharp JT, Assessment of radiologic progression in rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum 1986;29:1-9
   PubMed Web of Science ®Google Scholar
• Fries JF, Spitz P, Kraines RG, Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Giannini EH, Reiff A, Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Reiff A, Ilowite NT, Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Reiff A, Jones OY, Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94
   PubMed Web of Science ®Google Scholar
• Nielsen S, Ruperto N, Gerloni V, Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008;26:688-92
   PubMed Web of Science ®Google Scholar
• Poznanski AK, Hernandez RJ, Guire KE, Carpal length in children – a useful measurement in the diagnosis of rheumatoid arthritis and some concenital malformation syndromes. Radiology 1978;129:661-8
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M, American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-21
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Gulfe A, Saxne T, Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008;67:364-9
   PubMed Web of Science ®Google Scholar
• Daly M, Alikhan A, Armstrong AW. Combination systemic therapies in psoriatic arthritis. J Dermatolog Treat 2011 Oct; 22(1):276-84
   PubMedGoogle Scholar
• Spadaro A, Ceccarelli F, Scrivo R, Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis. Ann Rheum Dis 2008;67:1650-1
   PubMed Web of Science ®Google Scholar
• Heiberg MS, Koldingsnes W, Mikkelsen K, The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008;59:234-40
   PubMed Web of Science ®Google Scholar
• Duclos M, Gossec L, Ruyssen-Witrand A, Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 2006;33:2433-8
   PubMed Web of Science ®Google Scholar
• Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56
   PubMed Web of Science ®Google Scholar
• Anderson JJ, Baron G, van der Heijde D, Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86
   PubMed Web of Science ®Google Scholar
• Davis JC Jr, Van Der Heijde D, Braun J, Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6
   PubMed Web of Science ®Google Scholar
• Brandt J, Khariouzov A, Listing J, Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75
   PubMed Web of Science ®Google Scholar
• Calin A, Dijkmans BA, Emery P, Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600
   PubMed Web of Science ®Google Scholar
• Davis JC Jr, van der Heijde DM, Braun J, Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346-52
   PubMed Web of Science ®Google Scholar
• Dijkmans B, Emery P, Hakala M, Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 2009;36:1256-64
   PubMed Web of Science ®Google Scholar
• Brandt J, Listing J, Haibel H, Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford) 2005;44:342-8
   PubMed Web of Science ®Google Scholar
• Braun J, McHugh N, Singh A, Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford) 2007;46:999-1004
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Hermann KG, Landewe R, Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Ann Rheum Dis 2005;64:1141-4
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Golder W, Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Brandt J, Listing J, Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 2005;53:856-63
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT, Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-16
   PubMed Web of Science ®Google Scholar
• Feldman SR, Kimball AB, Krueger GG, Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol 2005;53:887-9
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Lowe N, A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32. discussion 32
   PubMed Web of Science ®Google Scholar
• Tyring S, Gottlieb A, Papp K, Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29-35
   PubMed Web of Science ®Google Scholar
• Tyring S, Gordon KB, Poulin Y, Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719-26
   PubMed Web of Science ®Google Scholar
• Gambichler T, Tigges C, Scola N, Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks. Br J Dermatol 2011;164:1383-6
   PubMed Web of Science ®Google Scholar
• Wolf P, Hofer A, Legat FJ, Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. Br J Dermatol 2009;160:186-9
   PubMed Web of Science ®Google Scholar
• De Simone C, D'Agostino M, Capizzi R, Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis. Eur J Dermatol 2011 July-Aug; 21(4):588-72
   Google Scholar
• Kircik L, Bagel J, Korman N, Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol 2008;7:245-53
   PubMed Web of Science ®Google Scholar
• Di Lernia V, Albertini G. Is antitumour necrosis factor therapy combined with ultraviolet B phototherapy safe? Br J Dermatol 2010;162:1147-8
   PubMed Web of Science ®Google Scholar
• Arida A, Fragiadaki K, Giavri E, Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011;41(1):61-70
   PubMed Web of Science ®Google Scholar
• Melikoglu M, Fresko I, Mat C, Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98-105
   PubMed Web of Science ®Google Scholar
• Saurenmann RK, Levin AV, Rose JB, Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006;45:982-9
   PubMed Web of Science ®Google Scholar
• Cantarini L, Tinazzi I, Caramaschi P, Safety and efficacy of etanercept in children with juvenile-onset Behcets disease. Int J Immunopathol Pharmacol 2009;22:551-5
   PubMed Web of Science ®Google Scholar
• Alty JE, Monaghan TM, Bamford JM. A patient with neuro-Behcet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade. Clin Neurol Neurosurg 2007;109:279-81
   PubMed Web of Science ®Google Scholar
• Aeberli D, Oertle S, Mauron H, Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly 2002;132:414-22
   PubMed Web of Science ®Google Scholar
• Curigliano V, Giovinale M, Fonnesu C, Efficacy of etanercept in the treatment of a patient with Behcet's disease. Clin Rheumatol 2008;27:933-6
   PubMed Web of Science ®Google Scholar
• Zhang MF, Zhao C, Wen X, The short-term efficacy and safety treatment study of recurrent uveitis in Behcet disease with etanercept. Zhonghua Yan Ke Za Zhi 2010;46:145-50
   PubMedGoogle Scholar
• Borhani Haghighi A. Treatment of neuro-Behcet's disease: an update. Expert Rev Neurother 2009;9:565-74
   PubMed Web of Science ®Google Scholar
• Singh JA, Christensen R, Wells GA, Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;CD007848
   PubMedGoogle Scholar
• Gottlieb AB, Gordon K, Giannini EH, Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol 2011;10:289-300
   PubMed Web of Science ®Google Scholar
• Data provided by Amgen
   Google Scholar
• Wood KL, Hage CA, Knox KS, Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med 2003;167:1279-82
   PubMed Web of Science ®Google Scholar
• Giles JT, Bathon JM. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004;19:320-34
   PubMedGoogle Scholar
• Zaman R, Abbas M. Case report of fatal disseminated histoplasmosis in a patient with rheumatoid arthritis following therapy with etanercept and methotrexate. In 40th Annual Meeting of the Infectious Diseases Society of America 2002; Chicago IL
   Google Scholar
• Bourre-Tessier J, Fortin C, Belisle A, Disseminated Histoplasma capsulatum infection presenting with panniculitis and focal myositis in rheumatoid arthritis treated with etanercept. Scand J Rheumatol 2009;38:311-16
   PubMed Web of Science ®Google Scholar
• Bakleh M, Tleyjeh I, Matteson EL, Infectious complications of tumor necrosis factor-alpha antagonists. Int J Dermatol 2005;44:443-8
   PubMed Web of Science ®Google Scholar
• Smitten AL, Choi HK, Hochberg MC, The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007;57:1431-8
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006;45:1370-5
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Listing J, Herzer P, Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301:737-44
   PubMed Web of Science ®Google Scholar
• Garcia-Doval I, Perez-Zafrilla B, Descalzo MA, Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 2010;69:1751-5
   PubMed Web of Science ®Google Scholar
• Salmon-Ceron D, Tubach F, Lortholary O, Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011;70:616-23
   PubMed Web of Science ®Google Scholar
• Bassetti S, Wasmer S, Hasler P, Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment. J Rheumatol 2005;32:2125-9
   PubMed Web of Science ®Google Scholar
• Jacobson JJ, Patel B, Asher G, Oral staphylococcus in older subjects with rheumatoid arthritis. J Am Geriatr Soc 1997;45:590-3
   PubMed Web of Science ®Google Scholar
• Jackson MS, Bagg J, Gupta MN, Oral carriage of staphylococci in patients with rheumatoid arthritis. Rheumatology (Oxford) 1999;38:572-5
   PubMed Web of Science ®Google Scholar
• Bassetti S, Dunagan DP, D'Agostino RB Jr, Nasal carriage of Staphylococcus aureus among patients receiving allergen-injection immunotherapy: associated factors and quantitative nasal cultures. Infect Control Hosp Epidemiol 2001;22:741-5
   PubMed Web of Science ®Google Scholar
• Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997;10:505-20
   PubMed Web of Science ®Google Scholar
• Bassetti S, Wolfisberg L, Jaussi B, Carriage of Staphylococcus aureus among injection drug users: lower prevalence in an injection heroin maintenance program than in an oral methadone program. Infect Control Hosp Epidemiol 2004;25:133-7
   PubMed Web of Science ®Google Scholar
• Sweet DD, Isac G, Morrison B, Purulent pericarditis in a patient with rheumatoid arthritis treated with etanercept and methotrexate. CJEM 2007;9:40-2
   PubMedGoogle Scholar
• Braun J, Baraliakos X, Brandt J, Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005;44:670-6
   PubMed Web of Science ®Google Scholar
• Mohan AK, Cote TR, Block JA, Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004;39:295-9
   PubMed Web of Science ®Google Scholar
• Carmona L, Hernandez-Garcia C, Vadillo C, Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003;30:1436-9
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Manadan AM, Poliyedath A, Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. J Rheumatol 2009;36:914-17
   PubMed Web of Science ®Google Scholar
• Frankel AJ, Van Voorhees AS, Hsu S, Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009;61:1044-55
   PubMed Web of Science ®Google Scholar
• Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-22
   PubMed Web of Science ®Google Scholar
• Gandhi RK, Pickup T, Sheth PB. Is etanercept safe for treating plaque psoriasis in a patient with chronic hepatitis C virus infection? Arch Dermatol 2010;146:1151-2
   PubMed Web of Science ®Google Scholar
• Zingarelli S, Frassi M, Bazzani C, Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 2009;36:1188-94
   PubMed Web of Science ®Google Scholar
• Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 69:1352-5
   PubMed Web of Science ®Google Scholar
• Elkayam O, Caspi D, Reitblatt T, The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004;33:283-8
   PubMed Web of Science ®Google Scholar
• Kapetanovic MC, Saxne T, Sjoholm A, Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006;45:106-11
   PubMed Web of Science ®Google Scholar
• Mease PJ, Ritchlin CT, Martin RW, Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004;31:1356-61
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-44
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Baecklund E, Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-20
   PubMed Web of Science ®Google Scholar
• Baecklund E, Iliadou A, Askling J, Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701
   PubMed Web of Science ®Google Scholar
• Grimpen F, Yeung D, Joseph J. Hepatosplenic T Cell lympoma, immunosuppressive agents and biologicals: what are the risks? J Gastroenterol Hepatol 2009;24:A311
   Google Scholar
• Beyer M, Steinhoff M, Anagnostopoulos I, Hepatosplenic T-cell lymphomas and therapy with TNF-alpha-blocking biologics: a risk for psoriasis patients? J Dtsch Dermatol Ges 2009;7:191-4
   PubMed Web of Science ®Google Scholar
• Praiser DM, Leonardi C, Gordon K, Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol 2011Oct 18 [Epub ahead of print]
   Google Scholar
• Gray DT, Suman VJ, Su WP, Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol 1997;133:735-40
   PubMed Web of Science ®Google Scholar
• Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985 – 1996. J Am Acad Dermatol 2001;45:528-36
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Shin DB, Neimann AL, The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126:2194-201
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Berlin J, Van Voorhees A, Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139:1425-9
   PubMed Web of Science ®Google Scholar
• Margolis D, Bilker W, Hennessy S, The risk of malignancy associated with psoriasis. Arch Dermatol 2001;137:778-83
   PubMed Web of Science ®Google Scholar
• Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol 2005;89:1-4
   PubMed Web of Science ®Google Scholar
• Reichgelt BA, Visser O. Epidemiology and survival of Merkel cell carcinoma in the Netherlands. A population-based study of 808 cases in 1993 – 2007. Eur J Cancer 2011;47:579-85
   PubMed Web of Science ®Google Scholar
• McCroskery P, Wallace CA, Lovell DJ, Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J 2010;8:18
   PubMed Web of Science ®Google Scholar
• Hayward K, Wallace CA. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009;11:216
   PubMed Web of Science ®Google Scholar
• Breda L, Del Torto M, De Sanctis S, Biologics in children's autoimmune disorders: efficacy and safety. Eur J Pediatr 2011;170:157-67
   PubMed Web of Science ®Google Scholar
• Diak P, Siegel J, La Grenade L, Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010;62:2517-24
   PubMed Web of Science ®Google Scholar
• Cron RQ, Beukelman T. Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA? Pediatr Rheumatol Online J 2010;8:23
   PubMed Web of Science ®Google Scholar
• Mercieca C, Vella N, Borg AA. Demyelination during anti-TNFalpha therapy for ankylosing spondylitis. Mod Rheumatol 2011 July; 12 [Epub ahead of print]
   Google Scholar
• Alshekhlee A, Basiri K, Miles JD, Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists. Muscle Nerve 41:723-7
   PubMed Web of Science ®Google Scholar
• Pfueller CF, Seipelt E, Zipp F, Multiple sclerosis following etanercept treatment for ankylosing spondylitis. Scand J Rheumatol 2008;37:397-9
   PubMed Web of Science ®Google Scholar
• Do HH, Mohamed A, Klistorner A, Ophthalmic manifestations of demyelination secondary to etanercept. Clin Experiment Ophthalmol 2008;36:392-4
   PubMed Web of Science ®Google Scholar
• Gomez-Gallego M, Meca-Lallana J, Fernandez-Barreiro A. Multiple sclerosis onset during etanercept treatment. Eur Neurol 2008;59:91-3
   PubMed Web of Science ®Google Scholar
• Fromont A, De Seze J, Fleury MC, Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 2009;45:55-7
   PubMed Web of Science ®Google Scholar
• Lozeron P, Denier C, Lacroix C, Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009;66:490-7
   PubMed Web of Science ®Google Scholar
• Cay HF, Gungor HA, Sezer I, Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report. J Clin Pharm Ther 2006;31:645-8
   PubMed Web of Science ®Google Scholar
• Mohan N, Edwards ET, Cupps TR, Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9
   PubMed Web of Science ®Google Scholar
• Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001;57:1885-8
   PubMed Web of Science ®Google Scholar
• Richez C, Blanco P, Lagueny A, Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology 2005;64:1468-70
   PubMed Web of Science ®Google Scholar
• van Oosten BW, Barkhof F, Truyen L, Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-4
   PubMed Web of Science ®Google Scholar
• The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-65
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50
   PubMed Web of Science ®Google Scholar
• Levine B, Kalman J, Mayer L, Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41
   PubMed Web of Science ®Google Scholar
• Deswal A, Bozkurt B, Seta Y, Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999;99:3224-6
   PubMed Web of Science ®Google Scholar
• Bozkurt B, Torre-Amione G, Warren MS, Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001;103:1044-7
   PubMed Web of Science ®Google Scholar
• Mann DL, McMurray JJ, Packer M, Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305-11
   PubMed Web of Science ®Google Scholar
• Yang DH, Chang DM, Lai JH, Etanercept as a rescue agent in patient with adult onset Still's disease complicated with congestive heart failure. Rheumatol Int 2008;29:95-8
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Cote TR, Cuffe MS, Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Leitch HA, Vickars LM, Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol 2003;71:396-8
   PubMed Web of Science ®Google Scholar
• Quartier P, Taupin P, Bourdeaut F, Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093-101
   PubMed Web of Science ®Google Scholar
• Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004;27:307-24
   PubMed Web of Science ®Google Scholar
• Feltelius N, Fored CM, Blomqvist P, Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005;64:246-52
   PubMed Web of Science ®Google Scholar
• Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 2011;50:619-25
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zeron P, Munoz S, Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242-51
   PubMed Web of Science ®Google Scholar
• Porfyridis I, Kalomenidis I, Psallidas I, Etanercept-induced pleuropericardial lupus-like syndrome. Eur Respir J 2009;33:939-41
   PubMed Web of Science ®Google Scholar
• Kang MJ, Lee YH, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci 2006;21:946-9
   PubMed Web of Science ®Google Scholar
• Carlson E, Rothfield N. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum 2003;48:1165-6. author reply 6
   PubMed Web of Science ®Google Scholar
• Jonsdottir T, Forslid J, van Vollenhoven A, Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 2004;63:1075-8
   PubMed Web of Science ®Google Scholar
• Amgen, Etanercept Physician Package Insert. 2003
   Google Scholar
• Shakoor N, Michalska M, Harris CA, Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579-80
   PubMed Web of Science ®Google Scholar
• Cairns AP, Duncan MK, Hinder AE, New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 2002;61:1031-2
   PubMed Web of Science ®Google Scholar
• Mohan AK, Edwards ET, Cote TR, Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 2002;360:646
   PubMed Web of Science ®Google Scholar
• De Bandt M, Sibilia J, Le Loet X, Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005;7:R545-51
   PubMed Web of Science ®Google Scholar
• Zeltser R, Valle L, Tanck C, Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol 2001;137:893-9
   PubMed Web of Science ®Google Scholar
• Gonzalez-Lopez MA, Martinez-Taboada VM, Gonzalez-Vela MC, Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis. Clin Exp Dermatol 2007;32:672-4
   PubMed Web of Science ®Google Scholar
• de Gannes GC, Ghoreishi M, Pope J, Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-31
   PubMed Web of Science ®Google Scholar
• Peek R, Scott-Jupp R, Strike H, Psoriasis after treatment of juvenile idiopathic arthritis with etanercept. Ann Rheum Dis 2006;65:1259
   PubMed Web of Science ®Google Scholar
• Chen LA, Su LH, Chang YJ, New-onset psoriasis associated with etanercept therapy. J Dermatol 37:378-80
   PubMed Web of Science ®Google Scholar
• Harrison MJ, Dixon WG, Watson KD, Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009;68:209-15
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Baumgartner SW, Weisman MH, Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006;65:379-84
   PubMed Web of Science ®Google Scholar
• Militello G, Xia A, Stevens SR, Etanercept for the treatment of psoriasis in the elderly. J Am Acad Dermatol 2006;55:517-19
   PubMed Web of Science ®Google Scholar
• Background Information For The Dermatologic and Ophthalmologic Drugs Advisory Committee (DODAC) Meeting 2008; Amgen Briefing Document for the United States Food and Drug Administration Dermatologic and Ophthalmic Drug Advisory Committee Meeting; 18 June 2008. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4361b2-02-AMGEN.pdf [ [Cited 11 February 2011]
   Google Scholar
• Reed SD, Vollan TA, Svec MA. Pregnancy outcomes in women with rheumatoid arthritis in Washington State. Matern Child Health J 2006;10:361-6
   PubMed Web of Science ®Google Scholar
• Murashima A, Watanabe N, Ozawa N, Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum. Ann Rheum Dis 2009;68:1793-4
   PubMed Web of Science ®Google Scholar
• Ostensen M, Eigenmann GO. Etanercept in breast milk. J Rheumatol 2004;31:1017-18
   PubMed Web of Science ®Google Scholar
• Boetticher NC, Peine CJ, Kwo P, A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008;135:1953-60
   PubMed Web of Science ®Google Scholar
• Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for N Engl J Med 2005;352:351-61
   Google Scholar
• Genovese MC, Cohen S, Moreland L, Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-19
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93
   PubMed Web of Science ®Google Scholar